Literature DB >> 25762686

Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Ana María Estrada-Sánchez1, Courtney L Burroughs1, Stephen Cavaliere1, Scott J Barton1, Shirley Chen1, X William Yang2, George V Rebec3.   

Abstract

Abnormal electrophysiological activity in the striatum, which receives dense innervation from the cerebral cortex, is believed to set the stage for the behavioral phenotype observed in Huntington's disease (HD), a neurodegenerative condition caused by mutation of the huntingtin (mhtt) protein. However, cortical involvement is far from clear. To determine whether abnormal striatal processing can be explained by mhtt alone (cell-autonomous model) or by mhtt in the corticostriatal projection cell-cell interaction model, we used BACHD/Emx1-Cre (BE) mice, a conditional HD model in which full-length mhtt is genetically reduced in cortical output neurons, including those that project to the striatum. Animals were assessed beginning at 20 weeks of age for at least the next 40 weeks, a range over which presymptomatic BACHD mice become symptomatic. Both open-field and nest-building behavior deteriorated progressively in BACHD mice relative to both BE and wild-type (WT) mice. Neuronal activity patterns in the dorsal striatum, which receives input from the primary motor cortex (M1), followed a similar age progression because BACHD activity changed more rapidly than either BE or WT mice. However, in the M1, BE neuronal activity differed significantly from both WT and BACHD. Although abnormal cortical activity in BE mice likely reflects input from mhtt-expressing afferents, including cortical interneurons, improvements in BE striatal activity and behavior suggest a critical role for mhtt in cortical output neurons in shaping the onset and progression of striatal dysfunction.
Copyright © 2015 the authors 0270-6474/15/354440-12$15.00/0.

Entities:  

Keywords:  BAC-Cre; BACHD mice; Huntington's disease; in vivo electrophysiology; motor cortex; striatum

Mesh:

Substances:

Year:  2015        PMID: 25762686      PMCID: PMC4355206          DOI: 10.1523/JNEUROSCI.2812-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.

Authors:  B Nicniocaill; B Haraldsson; O Hansson; W T O'Connor; P Brundin
Journal:  Eur J Neurosci       Date:  2001-01       Impact factor: 3.386

2.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

3.  Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex.

Authors:  D A McCormick; B W Connors; J W Lighthall; D A Prince
Journal:  J Neurophysiol       Date:  1985-10       Impact factor: 2.714

4.  Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Authors:  Paul G Unschuld; Suresh E Joel; Xinyang Liu; Megan Shanahan; Russell L Margolis; Kevin M Biglan; Susan S Bassett; David J Schretlen; Graham W Redgrave; Peter C M van Zijl; James J Pekar; Christopher A Ross
Journal:  Neurosci Lett       Date:  2012-03-07       Impact factor: 3.046

5.  Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

Authors:  J C Liévens; B Woodman; A Mahal; O Spasic-Boscovic; D Samuel; L Kerkerian-Le Goff; G P Bates
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

6.  Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release.

Authors:  He Li; Travis Wyman; Zhao-Xue Yu; Shi-Hua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2003-08-15       Impact factor: 6.150

7.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

8.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Authors:  Liliana Menalled; Bassem F El-Khodor; Monica Patry; Mayte Suárez-Fariñas; Samantha J Orenstein; Benjamin Zahasky; Christina Leahy; Vanessa Wheeler; X William Yang; Marcy MacDonald; A Jennifer Morton; Gill Bates; Janet Leeds; Larry Park; David Howland; Ethan Signer; Allan Tobin; Daniela Brunner
Journal:  Neurobiol Dis       Date:  2009-05-21       Impact factor: 5.996

9.  Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.

Authors:  S M de la Monte; J P Vonsattel; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

Review 10.  Role of cerebral cortex in the neuropathology of Huntington's disease.

Authors:  Ana M Estrada-Sánchez; George V Rebec
Journal:  Front Neural Circuits       Date:  2013-02-18       Impact factor: 3.492

View more
  22 in total

1.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

Review 2.  Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.

Authors:  Carlos Cepeda; Katerina D Oikonomou; Damian Cummings; Joshua Barry; Vannah-Wila Yazon; Dickson T Chen; Janelle Asai; Christopher K Williams; Harry V Vinters
Journal:  J Neurosci Res       Date:  2019-07-28       Impact factor: 4.164

3.  Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine.

Authors:  Claudia Rangel-Barajas; Ana María Estrada-Sánchez; Scott J Barton; Robert R Luedtke; George V Rebec
Journal:  Neuropharmacology       Date:  2016-11-02       Impact factor: 5.250

4.  TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.

Authors:  Xiaobei Zhao; Xu-Qiao Chen; Eugene Han; Yue Hu; Paul Paik; Zhiyong Ding; Julia Overman; Alice L Lau; Sarah H Shahmoradian; Wah Chiu; Leslie M Thompson; Chengbiao Wu; William C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

5.  Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Courtney L Blake; Scott J Barton; Andrew G Howe; George V Rebec
Journal:  J Neurophysiol       Date:  2019-11-06       Impact factor: 2.714

Review 6.  Molecular insights into cortico-striatal miscommunications in Huntington's disease.

Authors:  Matthew B Veldman; X William Yang
Journal:  Curr Opin Neurobiol       Date:  2017-11-07       Impact factor: 6.627

Review 7.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

8.  Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Daniel Castro; Kenia Portillo-Ortiz; Katrina Jang; Michael Nedjat-Haiem; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-10-11       Impact factor: 5.243

9.  Striatal network modeling in Huntington's Disease.

Authors:  Adam Ponzi; Scott J Barton; Kendra D Bunner; Claudia Rangel-Barajas; Emily S Zhang; Benjamin R Miller; George V Rebec; James Kozloski
Journal:  PLoS Comput Biol       Date:  2020-04-17       Impact factor: 4.475

Review 10.  Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

Authors:  C Frank Bennett; Adrian R Krainer; Don W Cleveland
Journal:  Annu Rev Neurosci       Date:  2019-07-08       Impact factor: 12.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.